title: Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function.
abstract: Nasal potential difference (NPD) measurement is part of the diagnostic criteria for cystic fibrosis (CF) and now used routinely as an endpoint in clinical trials of correcting the basic defect in CF. Intestinal current measurement (ICM), measured ex vivo on a rectal biopsy, has been used to study cystic fibrosis transmembrane conductance regulator (CFTR) function but has not been compared to NPD in the same subject in adults and children. The aim of the study is to evaluate the potential usefulness of ICM as a marker of CFTR function for treatment studies compared NPD in patients with CF and in healthy control subjects.
  
  
  
  ICM and NPD were performed on healthy controls and patients with CF. The healthy adults were individuals undergoing routine screening colonoscopy at the Beth Israel Deaconess Medical Center. The healthy children were undergoing colonoscopy for suspicion of inflammation in Hadassah Hebrew University Medical Center. The CF adults were recruited from Boston Children's Hospital CF Center and CF Center Worcester Mass, the children with CF from Hadassah CF Center.
  
  
  
  ICM measurements in healthy control subjects (n = 16) demonstrated a mean (±SE) carbachol response of 16.0 (2.2) μA/cm, histamine response of 13.2 (2.1) μA/cm and a forskolin response of 6.3 (2.0) μA/cm. Basal NPD of -15.9 (1.9) and response to Cl free + isoproterenol of -13.8 (2.0). These responses were inverted in CF subjects (n = 12) for ICM parameters with carbachol response of -3.0 (0.5) μA/cm, histamine -1.0 (0.8) μA/cm and a forskolin response of 0.5 (0.3) and also for NPD parameters; basal NPD of -42.2 (4.3) and response to Cl free + isoproterenol of 4.3 (0.7). Pearson correlation test showed the comparability of ICM and NPD in assessing CFTR function.
  
  
  
  ICM is equivalent to NPD in the ability to distinguish patients with CF from controls and could be used as surrogate markers of CFTR activity in treatment protocols.
authors: *Pediatric Gastroenterology Unit †CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel ‡Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel §Boston Children's Hospital, Harvard Medical School, Boston ||University of Massachusetts Medical School, Worcester, MA.
authors: Michael
authors: M
authors: Wilschanski
authors: Yasmin
authors: Y
authors: Yaakov
authors: Ibrahim
authors: I
authors: Omari
authors: Munir
authors: M
authors: Zaman
authors: Camilia R
authors: CR
authors: Martin
authors: Malena
authors: M
authors: Cohen-Cymberknoh
authors: David
authors: D
authors: Shoseyov
authors: Eitan
authors: E
authors: Kerem
authors: Deborah
authors: D
authors: Dasilva
authors: Sunil
authors: S
authors: Sheth
authors: Ahmet
authors: A
authors: Uluer
authors: Brian P
authors: BP
authors: OʼSullivan
authors: Steven
authors: S
authors: Freedman
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000175:diagnosis*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000378:metabolism*; D005260:Female; D006801:Humans; D007223:Infant; D007422:Intestines / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009666:Nose / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D019005:Cystic Fibrosis Transmembrane Conductance Regulator